Diligence memo · auto-generated · as of July 2, 2026
Innate Pharma, SA
Innate Pharma, SA looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Innate Pharma, SA operates in Pharmaceuticals, based in MARSEILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Innate Pharma, SA has raised $27M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2013-11-19.
Most recent recorded round closed around 2013-11-19.
Valuation (modeled)modeled
Provath models Innate Pharma, SA at approximately $932M (range $58M–$3.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.37× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (137% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 12.6 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 71% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.